Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
1 hedge funds and large institutions have $2.55K invested in Genetic Technologies Ltd. in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
266% more capital invested
Capital invested by funds: $697 → $2.55K (+$1.86K)
0% more funds holding
Funds holding: 1 → 1 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$305 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
RhumbLine Advisers
Boston,
Massachusetts
| $2.55K | -$305 | -399 | -11% |
|
GENE Hedge Fund Activity: Q2 2025 in Review
1 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q2 2025, worth a combined $2.55K — up 266% from $697 a quarter earlier.
Fund positioning in GENE was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was RhumbLine Advisers, cutting an estimated $305.
- 1 institutional investor held Genetic Technologies Ltd. (GENE) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $2.55K of Genetic Technologies Ltd. stock for Q2 2025, up 266% quarter-over-quarter.
- 0 funds opened new Genetic Technologies Ltd. positions in Q2 2025 and 0 closed out.
- The largest Genetic Technologies Ltd. seller in Q2 2025 was RhumbLine Advisers, an estimated $305 sold.
Based on aggregated 13F filings for Q2 2025.